 SEATTLE, Dec. 08, 2020 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq: ATOS, a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today the pricing of an underwritten public offering with expected total gross proceeds of 20.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company. 